HPN-217 *

HPN-217 is a B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®).

HPN-217 is being developed by Harpoon Therapeutics through Phase 1/2 clinical trials. AbbVie has an option to license worldwide exclusive rights to HPN-217 after completion of the Phase 1/2 trial. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities.

Type of Molecule

Biologic

Target

CD3-BCMA

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Multiple Myeloma in Relapse n/a
Phase 1